See more : Seadrill Limited (SDRL) Income Statement Analysis – Financial Results
Complete financial analysis of IGM Biosciences, Inc. (IGMS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IGM Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TIL Limited (TIL.BO) Income Statement Analysis – Financial Results
- Daicel Corporation (DACHF) Income Statement Analysis – Financial Results
- Quadrant Televentures Limited (QUADRANT.BO) Income Statement Analysis – Financial Results
- Wanhua Chemical Group Co., Ltd. (600309.SS) Income Statement Analysis – Financial Results
- Canadian Tire Corporation, Limited (CDNAF) Income Statement Analysis – Financial Results
IGM Biosciences, Inc. (IGMS)
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.13M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| Gross Profit | -6.15M | -9.53M | -7.72M | -3.58M | -2.33M | -278.00K | -161.00K |
| Gross Profit Ratio | -288.59% | -891.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 215.52M | 179.29M | 127.03M | 65.03M | 35.26M | 18.96M | 8.64M |
| General & Administrative | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Other Expenses | 0.00 | -181.00K | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Operating Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Cost & Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Interest Income | 17.74M | 7.04M | 159.00K | 1.93M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| EBITDA | -253.36M | -221.88M | -157.44M | -77.78M | -40.80M | -22.51M | -10.99M |
| EBITDA Ratio | -11,894.74% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -263.46M | -227.96M | -165.32M | -83.28M | -44.50M | -22.79M | -11.15M |
| Operating Income Ratio | -12,369.06% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.72M | 6.85M | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Income Before Tax | -245.74M | -221.10M | -165.16M | -81.36M | -43.13M | -22.71M | -11.05M |
| Income Before Tax Ratio | -11,537.00% | -20,683.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 678.00K | -6.85M | -4.48M | -1.03M | -597.00K | 80.00K | 0.00 |
| Net Income | -246.42M | -214.25M | -160.68M | -80.33M | -42.54M | -22.71M | -11.05M |
| Net Income Ratio | -11,568.83% | -20,041.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| EPS Diluted | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| Weighted Avg Shares Out | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
| Weighted Avg Shares Out (Dil) | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC
Medivir to present at the Erik Penser Bank Company Event
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates
IGM Biosciences Announces Second Quarter 2023 Financial Results
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
IGM Announces Proposed Public Offering and Concurrent Private Placement
Source: https://incomestatements.info
Category: Stock Reports